Navigation Links
Epicel(TM) Wins Marketing Approval for Severe Burn Victims
Date:10/29/2007

First FDA-Approved Xenotransplantation Device

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) announced today that the U.S. Food and Drug Administration (FDA) has granted Epicel(TM) (cultured epidermal autografts) marketing approval under the Humanitarian Device Exemption (HDE) for the treatment of life-threatening wounds resulting from severe burns. It is a product that can provide permanent skin replacement for burn victims, and is made from a patient's own skin cells and then grown on a layer of mouse cells to enhance growth. Epicel is the first xenotransplantation-classified product to be approved in the U.S. because of its inclusion of animal cells.

"We are pleased that the FDA has recognized the importance of Epicel for patients with severe burns," said Alicia Secor, vice president and general manager of the Biosurgical Specialties group within Genzyme that manufactures Epicel. "Epicel has played a critical role in the recovery process of hundreds of patients who have suffered through the trauma of life-threatening burns."

Epicel has been used in more than 1,000 patients with burn injuries since it was introduced in 1988. The product had been considered a banked human tissue until 1996 when FDA announced that manipulated autologous cell-based products used for structural repair or reconstruction required regulatory oversight. Genzyme applied for regulatory approval of Epicel in 1999.

Epicel is supplied in grafts, which each consist of a sheet of cultured epidermal cells attached with stainless steel surgical clips to a backing of petrolatum gauze. Enough skin can be grown from a biopsy the size of a postage stamp to cover the entire body. The process takes approximately 16 days and the skin grafts integrate with surrounding tissue 3 to 4 weeks after surgery.

"Epicel has been the most important advance in burn care for the coverage of large total body surface area burn wounds in this decade," said Dr. Rajiv Sood, medical director, Richard M. Fairbanks Burn Center, Indiana University School of Medicine.

About Epicel

Epicel is indicated for use in patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30 percent. It may be used in conjunction with split-thickness autografts -- another type of skin graft taken from a patient's body to treat the burned area -- or alone in patients for whom these autografts may not be an option due to the severity and extent of their burns. The effectiveness of the device for this use has not been demonstrated.

Epicel is contraindicated in patients with known hypersensitivity to agents used in the manufacture of Epicel. Epicel should not be used in patients with a known history of anaphylaxis to vancomycin or amikacin. Epicel is cultured in media containing vancomycin and amikacin. Trace quantities of these antibiotics may adhere to the Epicel autograft.

Epicel should not be used in patients with known sensitivities to materials of bovine or murine origin. The cell culture medium used in the culture of Epicel contains bovine serum and the cells co-cultured with murine 3T3 fibroblasts. The medium used to package and transport Epicel does not contain serum; however, trace quantities of bovine derived proteins may be present. This tissue is intended for autologous use and has not been tested for biohazards. Health care providers should handle this product as if infectious agents are present.

During the Epicel manufacturing, patient's cells are co-cultured with mouse cells. Although the mouse cells have been tested and found to be free of bacteria, fungi and virus, an infection can not be excluded. It is also possible that symptoms of an infection may not be seen for months or years. To date, Genzyme Biosurgery is not aware of any infections related to mouse cells. As a safety measure, the Epicel treated patients are precluded from donation of blood or blood parts, tissue, breast milk, egg, sperm, or other body parts for use in humans.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.

Media Contact: Investor Contact:

Maria Cantor Catherine Forte

(617) 768-6690 (617) 768-6881


'/>"/>
SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA To Set New Guidelines To Revise Drug Companies Marketing Tactics
2. Junk Food Marketing to be banned
3. Government Should Restrict Junk Food Marketing
4. Kellogg Warned Against Its Marketing Strategies
5. Marketing of Low Tar Cigarette Brand by BAT Unethical
6. Bayer Wins Positive Response For Marketing Its Cancer Drug
7. Co-op to Stop Marketing Diabetic Food
8. Measures to Streamline Marketing of Breast-Milk Substitutes
9. Marketing in Schools may Discourage Healthy Nutrition among Students
10. Viagra Marketing Campaign, ‘a Cause of Concern’, Say Anti-AIDS Grop
11. Effective Marketing of Multivitamins Essential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: